A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

NCT00283114 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

82

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndrome
Myeloproliferative Disorders
Chronic Myelomonocytic Leukemia

Interventions

DRUG: lintuzumab

Sponsor

Seagen Inc.